CN108658983B - 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用 - Google Patents

用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用 Download PDF

Info

Publication number
CN108658983B
CN108658983B CN201810661179.3A CN201810661179A CN108658983B CN 108658983 B CN108658983 B CN 108658983B CN 201810661179 A CN201810661179 A CN 201810661179A CN 108658983 B CN108658983 B CN 108658983B
Authority
CN
China
Prior art keywords
compound
deuterium
hydrogen
cancer
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810661179.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN108658983A (zh
Inventor
王义汉
刘志强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Targetrx Inc
Original Assignee
Shenzhen Targetrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Targetrx Inc filed Critical Shenzhen Targetrx Inc
Priority to CN201911104054.1A priority Critical patent/CN110759908B/zh
Publication of CN108658983A publication Critical patent/CN108658983A/zh
Application granted granted Critical
Publication of CN108658983B publication Critical patent/CN108658983B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201810661179.3A 2017-06-26 2018-06-25 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用 Active CN108658983B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911104054.1A CN110759908B (zh) 2017-06-26 2018-06-25 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710493544 2017-06-26
CN201710493544X 2017-06-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201911104054.1A Division CN110759908B (zh) 2017-06-26 2018-06-25 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用

Publications (2)

Publication Number Publication Date
CN108658983A CN108658983A (zh) 2018-10-16
CN108658983B true CN108658983B (zh) 2019-12-20

Family

ID=63772870

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201911104054.1A Active CN110759908B (zh) 2017-06-26 2018-06-25 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
CN201810661179.3A Active CN108658983B (zh) 2017-06-26 2018-06-25 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201911104054.1A Active CN110759908B (zh) 2017-06-26 2018-06-25 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用

Country Status (6)

Country Link
US (1) US11718611B2 (enExample)
EP (1) EP3626241B1 (enExample)
JP (2) JP7374496B2 (enExample)
CN (2) CN110759908B (enExample)
ES (1) ES3028360T3 (enExample)
WO (1) WO2019001383A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111747949B (zh) * 2019-03-29 2022-07-01 首药控股(北京)股份有限公司 Bcl-2选择性抑制剂的制备方法
IL296582A (en) 2020-04-15 2022-11-01 Beigene Ltd bcl-2 inhibitor
CN111537654B (zh) * 2020-07-07 2020-11-10 上海亚盛医药科技有限公司 N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法
KR20230038231A (ko) * 2020-07-10 2023-03-17 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 술포닐벤즈아미드 유도체 및 이의 접합체, 이의 제조 방법 및 이의 용도
CN114835704B (zh) * 2021-02-01 2023-10-27 苏州亚盛药业有限公司 作为bcl-2抑制剂的磺酰基苯甲酰胺衍生物
WO2024032776A1 (en) * 2022-08-12 2024-02-15 Fochon Biosciences, Ltd. Compounds as bcl-2 inhibitors
CN115286689B (zh) * 2022-09-29 2023-01-06 上海睿跃生物科技有限公司 靶向降解Bcl-2蛋白的化合物及其应用和药物
CN115872963A (zh) * 2022-12-27 2023-03-31 南京哈柏医药科技有限公司 一种维奈托克中间体的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US20100160322A1 (en) * 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
PE20120345A1 (es) 2009-05-26 2012-05-17 Abbvie Bahamas Ltd Derivados de 2-(1h-pirrolo[2,3-b]piridin-5-iloxi)-n-fenilsulfonilbenzamida como inhibidores de proteinas anti-apoptoticas
MY165884A (en) * 2010-11-23 2018-05-18 Abbvie Ireland Unlimited Co Methods of treatment using selective bcl-2 inhibitors
SG190361A1 (en) 2010-11-23 2013-06-28 Abbvie Inc Salts and crystalline forms of an apoptosis-inducing agent
US8889675B2 (en) * 2011-10-14 2014-11-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20190225607A1 (en) * 2016-07-06 2019-07-25 Concert Pharmaceuticals, Inc. Deuterated Venetoclax

Also Published As

Publication number Publication date
EP3626241A1 (en) 2020-03-25
ES3028360T3 (en) 2025-06-19
US11718611B2 (en) 2023-08-08
JP7374496B2 (ja) 2023-11-07
CN110759908A (zh) 2020-02-07
CN108658983A (zh) 2018-10-16
US20200216442A1 (en) 2020-07-09
WO2019001383A1 (zh) 2019-01-03
JP2022071077A (ja) 2022-05-13
JP2020527166A (ja) 2020-09-03
EP3626241B1 (en) 2025-04-23
CN110759908B (zh) 2021-03-12
EP3626241A4 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
CN108658983B (zh) 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
JP7710223B2 (ja) 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用
WO2022017533A1 (zh) 用作cdk7激酶抑制剂的化合物及其应用
WO2020114388A1 (zh) 取代的吡唑并[1,5-a]吡啶化合物及包含该化合物的组合物及其用途
WO2019001379A1 (zh) 用于抑制激酶活性的吲唑类化合物及其组合物及应用
EP4155304B1 (en) Compound used as ret kinase inhibitor and application thereof
JP2024050645A (ja) ヘテロアリールで置換されたピラゾール化合物及びその医薬用途
TW201718583A (zh) 新的表皮生長因子受體抑制劑及其應用
CN111763215A (zh) 一种具有含氮杂环结构的化合物及其制备方法和用途
WO2019154091A1 (zh) 取代的二氨基嘧啶化合物
CN106957315A (zh) N-取代苯磺酰基-氮杂吲哚氧基苯甲酰胺类化合物及其制备药物的用途
CN115785107A (zh) 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途
WO2019042187A1 (zh) 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
WO2019228330A1 (zh) 取代的苯并[d]咪唑类化合物及其药物组合物
CN107501279A (zh) 呋喃并喹啉二酮类化合物及其医药用途
KR102270538B1 (ko) 이코티닙 포스페이트의 신규한 다형체 형태 및 이의 용도
EP4596553A1 (en) Salt of dioxane quinoline compound, crystal form thereof, preparation methods therefor and uses thereof
US20190062307A1 (en) Deuterium-substituted quinoline derivatives
TWI596098B (zh) 埃克替尼馬來酸鹽的晶型及其用途
HK40061853B (zh) 用作cdk7激酶抑制剂的化合物及其应用
CN110950773A (zh) 联苯二酚酰胺衍生物及其作为抗癌药物的应用
CN108368052A (zh) 半对甲苯磺酸索拉非尼一水合物结晶及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant